secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcellx, Inc. (ACLX)
CIK:        0001786205
Form:       8-K
Filed at:   2023-12-12T23:59:59+00:00
Accession:  0001193125-23-293003
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcellx presents CART-ddBCMA Phase 1 expansion data at ASH; no specific results disclosed in 8-K
--------------------------------------------------------------------------------

- Event at 65th ASH Annual Meeting on Dec 11, 2023 in San Diego highlighting CART-ddBCMA Phase 1 expansion trial.
- Trial enrolled patients with relapsed/refractory multiple myeloma.
- Filing does not include numerical efficacy or safety data from the presentation.
- Corporate slides attached as Exhibit 99.1 but full data not reproduced in this filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1786205/000119312523293003/0001193125-23-293003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1786205/000119312523293003/d659269d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-293003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer